4D Molecular Therapeutics (FDMT) Leases (2021 - 2025)
Historic Leases for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $18.9 million.
- 4D Molecular Therapeutics' Leases fell 1311.92% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year decrease of 1311.92%. This contributed to the annual value of $21.1 million for FY2024, which is 8263.28% up from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Leases of $18.9 million as of Q3 2025, which was down 1311.92% from $19.6 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Leases ranged from a high of $21.8 million in Q3 2024 and a low of $10.7 million during Q2 2024
- For the 5-year period, 4D Molecular Therapeutics' Leases averaged around $15.1 million, with its median value being $13.6 million (2022).
- Per our database at Business Quant, 4D Molecular Therapeutics' Leases plummeted by 1347.15% in 2024 and then skyrocketed by 8384.17% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Leases stood at $14.6 million in 2021, then fell by 10.14% to $13.1 million in 2022, then decreased by 11.82% to $11.5 million in 2023, then surged by 82.63% to $21.1 million in 2024, then decreased by 10.28% to $18.9 million in 2025.
- Its Leases stands at $18.9 million for Q3 2025, versus $19.6 million for Q2 2025 and $20.4 million for Q1 2025.